Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute in the USA, posted on X:

“Presenting the story of Hydra and Cancer – ‘Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. Acquired NTRK3 fusion, ALK fusion, NTRK3 solvent-front mutation as secondary, tertiary, and quaternary off-target resistance mechanisms’ Cancer – akin to the mythical Hydra, whose 9 heads must be all severed, as two heads grow back if one is slayed.

Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET-driven cancer | Precision Oncology

Battling the 9-headed cancer Hydra (akin to Cancer) with multiple modalities. Cutting off a head may result in two heads growing back (akin to the emergence of resistance mutations when a single mutation is targeted).”

Read further.
Source: Vivek Subbiah/X